In a surprising political pivot, Donald Trump is reportedly preparing to reclassify marijuana, a move that could reshape both U.S. drug policy and his strained relationship with key supporters.
The decision—expected imminently—would shift cannabis from a Schedule I drug (alongside substances like heroin and LSD) to Schedule III, a category that allows broader medical research and acknowledges potential therapeutic benefits.
But behind the policy lies a deeper political calculation.
⚠️ A Strategy Born From Political Pressure
Trump’s relationship with influential online voices—particularly podcasters—has cooled in recent months.
Figures like Joe Rogan, once seen as powerful allies, have publicly criticized the administration over:
- The ongoing war with Iran
- Controversies surrounding the Epstein files
- Immigration policies
These voices command millions of listeners, especially among younger male voters—a group that played a crucial role in Trump’s political resurgence.
Now, the White House appears to be making a targeted move to win them back.
🌿 The Marijuana Shift
Reclassifying marijuana would:
- Expand medical research opportunities
- Reduce regulatory barriers
- Signal a softer stance on drug policy
Officials say the move builds on an earlier executive order aimed at accelerating research into both cannabis and psychedelic treatments for mental health conditions.
At a recent White House event, Trump even pressed aides publicly to “get the rescheduling done”, underscoring urgency behind the decision.
🎙️ The Podcast Factor
The influence of the “manosphere”—a loose network of podcast hosts and online commentators—has grown dramatically in recent years.
Joe Rogan alone reaches an audience of around 11 million per episode, often shaping political opinions among younger demographics.
During the 2024 campaign, these platforms gave Trump direct access to voters outside traditional media. Now, with that support wavering, the administration appears eager to rebuild those bridges.
💊 Beyond Cannabis: Psychedelics Enter the Conversation
The marijuana move comes alongside broader interest in alternative therapies.
Trump recently signed an order accelerating review of psychedelic treatments, including substances like ibogaine, which has been promoted for treating addiction and mental illness.
The initiative reportedly includes $50 million in research funding, though experts warn of potential risks and side effects.
📉 A Base in Flux
Recent data suggests Trump’s support among key voter groups is slipping:
- Declines among non-college-educated white voters
- Growing criticism from right-wing commentators
- Fractures within the broader MAGA movement
Even some of his most vocal former allies have described recent policies as a “betrayal.”
⚖️ Policy or Politics?
The big question remains:
👉 Is this a genuine shift in drug policy—or a strategic attempt to regain political ground?
Supporters argue the move modernizes outdated laws and supports medical innovation.
Critics say it’s a calculated effort to win back influential voices and stabilize a shaky base.
⏳ What Comes Next?
If the reclassification goes through, it could mark one of the most significant changes in U.S. drug policy in decades.
But politically, the stakes are just as high.
With midterm elections approaching and internal divisions growing, Trump is navigating a delicate balancing act—trying to hold together a coalition that no longer seems as unified as it once was.
📊 The Bottom Line
This isn’t just about marijuana.
It’s about influence, loyalty, and the evolving power of digital media in American politics.
And in that battle, every move—policy or not—carries weight.